Inovio Historical Balance Sheet

INO Stock

USD 4.19 0.18 4.49%

Trend analysis of Inovio Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 23.4 M or Total Stockholder Equity of 95.2 M provides information on Inovio Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Inovio Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Inovio Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Inovio Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inovio Pharmaceuticals is a good buy for the upcoming year.

Inovio Pharmaceuticals Inventory

342,573

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

About Inovio Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Inovio Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Inovio Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Inovio Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Inovio currently owns. An asset can also be divided into two categories, current and non-current.

Inovio Pharmaceuticals Balance Sheet Chart

At this time, Inovio Pharmaceuticals' Other Stockholder Equity is very stable compared to the past year. As of the 28th of November 2024, Property Plant And Equipment Gross is likely to grow to about 37.1 M, while Total Assets are likely to drop about 131.2 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity Other Stockholder Equity Current Deferred Revenue

Add Fundamental

Total Assets

Total assets refers to the total amount of Inovio Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Inovio Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Inovio Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Inovio Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most accounts from Inovio Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Other Stockholder Equity is very stable compared to the past year. As of the 28th of November 2024, Property Plant And Equipment Gross is likely to grow to about 37.1 M, while Total Assets are likely to drop about 131.2 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	33.0M	32.1M	30.2M	21.9M
Total Assets	495.9M	348.5M	172.9M	131.2M

Short Long Term Debt Total Total Assets

Inovio Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Other Current Liab	Other Liab	Non Currrent Assets Other	Other Assets	Long Term Debt	Common Stock Total Equity
Total Assets		-0.34	0.71	0.97	0.77	-0.62	-0.53	0.59	0.79	0.67	1.0	0.75	-0.21	0.32	0.88	0.65	0.63	0.61	1.0	-0.36	0.66	-0.29	0.11	0.63	0.08	-0.32
Short Long Term Debt Total	-0.34		-0.26	-0.35	-0.2	0.1	0.57	-0.26	-0.21	0.35	-0.38	-0.13	0.68	0.0	-0.5	-0.59	-0.15	-0.5	-0.4	0.8	-0.4	0.81	-0.21	-0.17	0.11	-0.51
Total Current Liabilities	0.71	-0.26		0.59	0.66	-0.11	-0.67	0.81	0.26	0.39	0.69	0.59	-0.06	0.29	0.81	0.69	0.78	0.52	0.72	-0.33	0.84	-0.15	0.23	0.11	0.19	-0.38
Total Stockholder Equity	0.97	-0.35	0.59		0.63	-0.75	-0.43	0.48	0.83	0.62	0.97	0.74	-0.14	0.11	0.82	0.58	0.42	0.52	0.97	-0.31	0.53	-0.36	0.06	0.67	-0.08	-0.27
Property Plant And Equipment Net	0.77	-0.2	0.66	0.63		-0.14	-0.57	0.66	0.46	0.67	0.76	0.46	-0.17	0.7	0.62	0.61	0.85	0.77	0.75	-0.41	0.59	0.08	0.21	0.39	0.57	-0.3
Net Debt	-0.62	0.1	-0.11	-0.75	-0.14		-0.07	0.11	-0.9	-0.5	-0.61	-0.66	-0.05	0.21	-0.47	-0.08	0.07	0.05	-0.61	0.02	-0.19	0.21	0.07	-0.84	0.26	0.09
Retained Earnings	-0.53	0.57	-0.67	-0.43	-0.57	-0.07		-0.52	-0.16	-0.12	-0.54	-0.25	0.31	-0.3	-0.58	-0.98	-0.59	-0.85	-0.55	0.55	-0.64	0.44	-0.19	-0.09	-0.24	0.35
Accounts Payable	0.59	-0.26	0.81	0.48	0.66	0.11	-0.52		0.01	0.25	0.59	0.27	-0.06	0.27	0.67	0.55	0.65	0.6	0.6	-0.33	0.65	-0.11	0.18	-0.18	0.25	-0.2
Cash	0.79	-0.21	0.26	0.83	0.46	-0.9	-0.16	0.01		0.65	0.78	0.7	-0.22	0.22	0.62	0.31	0.3	0.23	0.77	-0.22	0.4	-0.24	0.01	0.95	0.02	-0.17
Non Current Assets Total	0.67	0.35	0.39	0.62	0.67	-0.5	-0.12	0.25	0.65		0.62	0.69	0.27	0.44	0.39	0.23	0.52	0.31	0.61	0.18	0.26	0.37	0.07	0.62	0.31	-0.62
Cash And Short Term Investments	1.0	-0.38	0.69	0.97	0.76	-0.61	-0.54	0.59	0.78	0.62		0.71	-0.24	0.3	0.87	0.67	0.6	0.63	1.0	-0.41	0.64	-0.34	0.1	0.61	0.06	-0.29
Net Receivables	0.75	-0.13	0.59	0.74	0.46	-0.66	-0.25	0.27	0.7	0.69	0.71		0.09	0.1	0.63	0.37	0.41	0.21	0.73	-0.08	0.42	-0.08	0.15	0.65	-0.08	-0.25
Common Stock Shares Outstanding	-0.21	0.68	-0.06	-0.14	-0.17	-0.05	0.31	-0.06	-0.22	0.27	-0.24	0.09		-0.43	-0.4	-0.31	-0.32	-0.3	-0.25	0.49	-0.37	0.72	-0.19	-0.21	0.0	-0.38
Non Current Liabilities Total	0.32	0.0	0.29	0.11	0.7	0.21	-0.3	0.27	0.22	0.44	0.3	0.1	-0.43		0.27	0.27	0.83	0.44	0.29	-0.28	0.4	0.2	0.13	0.23	0.67	-0.19
Other Current Assets	0.88	-0.5	0.81	0.82	0.62	-0.47	-0.58	0.67	0.62	0.39	0.87	0.63	-0.4	0.27		0.67	0.65	0.48	0.89	-0.42	0.87	-0.5	0.14	0.47	0.03	-0.17
Other Stockholder Equity	0.65	-0.59	0.69	0.58	0.61	-0.08	-0.98	0.55	0.31	0.23	0.67	0.37	-0.31	0.27	0.67		0.58	0.87	0.67	-0.56	0.65	-0.48	0.18	0.21	0.19	-0.36
Total Liab	0.63	-0.15	0.78	0.42	0.85	0.07	-0.59	0.65	0.3	0.52	0.6	0.41	-0.32	0.83	0.65	0.58		0.6	0.61	-0.38	0.76	0.04	0.22	0.21	0.55	-0.34
Property Plant And Equipment Gross	0.61	-0.5	0.52	0.52	0.77	0.05	-0.85	0.6	0.23	0.31	0.63	0.21	-0.3	0.44	0.48	0.87	0.6		0.62	-0.54	0.43	-0.28	0.22	0.15	0.35	-0.28
Total Current Assets	1.0	-0.4	0.72	0.97	0.75	-0.61	-0.55	0.6	0.77	0.61	1.0	0.73	-0.25	0.29	0.89	0.67	0.61	0.62		-0.41	0.67	-0.35	0.11	0.61	0.05	-0.28
Intangible Assets	-0.36	0.8	-0.33	-0.31	-0.41	0.02	0.55	-0.33	-0.22	0.18	-0.41	-0.08	0.49	-0.28	-0.42	-0.56	-0.38	-0.54	-0.41		-0.44	0.41	-0.04	-0.13	-0.22	-0.41
Other Current Liab	0.66	-0.4	0.84	0.53	0.59	-0.19	-0.64	0.65	0.4	0.26	0.64	0.42	-0.37	0.4	0.87	0.65	0.76	0.43	0.67	-0.44		-0.34	0.21	0.29	0.34	-0.23
Other Liab	-0.29	0.81	-0.15	-0.36	0.08	0.21	0.44	-0.11	-0.24	0.37	-0.34	-0.08	0.72	0.2	-0.5	-0.48	0.04	-0.28	-0.35	0.41	-0.34		-0.14	-0.19	0.37	-0.28
Non Currrent Assets Other	0.11	-0.21	0.23	0.06	0.21	0.07	-0.19	0.18	0.01	0.07	0.1	0.15	-0.19	0.13	0.14	0.18	0.22	0.22	0.11	-0.04	0.21	-0.14		0.07	0.16	0.07
Other Assets	0.63	-0.17	0.11	0.67	0.39	-0.84	-0.09	-0.18	0.95	0.62	0.61	0.65	-0.21	0.23	0.47	0.21	0.21	0.15	0.61	-0.13	0.29	-0.19	0.07		0.08	-0.1
Long Term Debt	0.08	0.11	0.19	-0.08	0.57	0.26	-0.24	0.25	0.02	0.31	0.06	-0.08	0.0	0.67	0.03	0.19	0.55	0.35	0.05	-0.22	0.34	0.37	0.16	0.08		-0.16
Common Stock Total Equity	-0.32	-0.51	-0.38	-0.27	-0.3	0.09	0.35	-0.2	-0.17	-0.62	-0.29	-0.25	-0.38	-0.19	-0.17	-0.36	-0.34	-0.28	-0.28	-0.41	-0.23	-0.28	0.07	-0.1	-0.16

Click cells to compare fundamentals

Inovio Pharmaceuticals Account Relationship Matchups

Inovio Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	144.0M	539.8M	495.9M	348.5M	172.9M	131.2M
Total Current Liabilities	32.0M	41.7M	65.7M	96.9M	42.6M	23.4M
Total Stockholder Equity	3.4M	461.1M	399.7M	222.4M	117.3M	95.2M
Property Plant And Equipment Net	26.6M	24.1M	29.0M	18.0M	14.5M	7.5M
Net Debt	77.3M	(211.7M)	(38.1M)	(14.3M)	15.9M	16.7M
Retained Earnings	(739.8M)	(906.2M)	(1.2B)	(1.5B)	(1.6B)	(1.5B)
Accounts Payable	7.6M	1.5M	28.0M	21.1M	4.6M	5.0M
Cash	22.2M	250.7M	71.1M	46.3M	14.3M	13.6M
Non Current Assets Total	49.8M	68.6M	47.5M	33.3M	19.8M	28.2M
Cash And Short Term Investments	89.5M	411.6M	401.3M	253.0M	145.3M	92.0M
Net Receivables	2.0M	19.1M	8.0M	11.7M	2.4M	3.9M
Common Stock Shares Outstanding	8.2M	12.9M	17.4M	19.9M	22.2M	28.0M
Liabilities And Stockholders Equity	144.0M	539.8M	495.9M	348.5M	172.9M	131.2M
Non Current Liabilities Total	106.6M	36.9M	30.5M	29.3M	13.0M	12.1M
Other Current Assets	2.6M	40.5M	39.1M	50.5M	5.4M	6.9M
Other Stockholder Equity	742.6M	1.4B	1.6B	1.7B	1.7B	1.8B
Total Liab	138.5M	78.6M	96.3M	126.2M	55.6M	35.5M
Property Plant And Equipment Gross	26.6M	24.1M	48.0M	18.0M	35.3M	37.1M
Total Current Assets	94.2M	471.2M	448.4M	315.2M	153.1M	103.0M
Accumulated Other Comprehensive Income	472.6K	(256.2K)	(282.2K)	(698.7K)	(662.6K)	(629.5K)
Intangible Assets	3.7M	3.1M	2.6M	2.1M	2.4M	2.3M
Other Current Liab	22.1M	37.9M	35.1M	73.0M	18.7M	11.5M
Other Liab	9.1M	206.4K	111.2K	32.0K	36.9K	35.0K
Non Currrent Assets Other	(5.4M)	22.2M	(1.5M)	(1.6M)	605.3K	635.6K
Other Assets	2.7M	43.6M	1.4M	684.0K	1.0	0.95
Common Stock Total Equity	101.4K	186.9K	217.4K	253.1K	227.8K	216.4K
Common Stock	101.4K	186.9K	217.4K	253.1K	22.8K	21.7K
Property Plant Equipment	12.8M	11.3M	17.5M	7.7M	8.9M	5.2M
Current Deferred Revenue	257.2K	124.1K	46.6K	21.6K	24.9K	23.6K
Short Term Investments	67.3M	160.9M	330.2M	206.7M	131.0M	85.0M
Net Tangible Assets	(10.8M)	447.5M	386.5M	209.7M	241.2M	159.6M
Retained Earnings Total Equity	(739.8M)	(906.2M)	(1.2B)	(1.5B)	(1.3B)	(1.3B)
Capital Surpluse	742.6M	1.4B	1.6B	1.7B	2.0B	2.1B

When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:

How To Invest In Inovio

Details

Is Inovio Stock a good investment?

Details

What is Inovio Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.43)

Revenue Per Share

0.025

Quarterly Revenue Growth

(0.55)

Return On Assets

(0.40)

Return On Equity

(0.91)

The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inovio Historical Balance Sheet

Inovio Pharmaceuticals Inventory

342,573

About Inovio Balance Sheet Analysis

Inovio Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Current Deferred Revenue

Inovio Pharmaceuticals balance sheet Correlations

Inovio Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inovio Pharmaceuticals balance sheet Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.97	Total Assets
Cash And Short Term Investments	+ 0.97	Total Stockholder Equity
Total Current Assets	+ 0.97	Total Stockholder Equity

Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.9	Net Debt
Property Plant And Equipment Gross	- 0.85	Retained Earnings
Other Assets	- 0.84	Net Debt
Net Debt	- 0.75	Total Stockholder Equity
Retained Earnings	- 0.67	Total Current Liabilities